TWiV 955: Clinical update with Dr. Daniel Griffin

November 19, 2022

In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution.

Click arrow to play
Download TWiV 955 (28 MB .mp3, 47 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

Leave a Reply

Your email address will not be published. Required fields are marked *

2 comments on “TWiV 955: Clinical update with Dr. Daniel Griffin

  1. with regard to the letter from Susan from London, Ontario:

    For a short time the Moderna bivalent vaccine approved in Canada was for wild type and omicron BA.1. This was at the same time as the bivalent BA.4/5 Pfizer vaccine was out and the BA4/5 Moderna vaccine was first available in the US. Shortly after the newer Moderna vaccine with BA4/5 was approved and became available in Canada. Why Moderna sought approval of the BA.1 vaccine and why Health Canada approved it when the BA.4/5 vaccine was imminent is rather a mystery.

  2. Would it make sense to follow on the microglia discussion by having Jarred Younger on Immune?